Lumoxiti

Generic name: Moxetumomab Pasudotox
Drug class: Miscellaneous antineoplastics

Usage of Lumoxiti

Lumoxiti is an injection used to treat hairy cell leukemia.

Lumoxiti is used in adult patients with hairy cell leukemia that has relapsed.

Lumoxiti is also used if the patient has not responded to previous treatments, and has received at least 2 other treatments, including a type of medicine called purine nucleoside analog (PNA).

It is not known if Lumoxiti is safe and effective in children.

Lumoxiti side effects

Get emergency medical help if you have signs of an allergic reaction to Lumoxiti: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver if you feel dizzy, nauseated, hot or cold, light-headed, or have a headache, muscle pain, cough, trouble breathing, or fast heartbeats.

Lumoxiti can damage red blood cells, which may cause irreversible kidney failure. Get emergency medical help if you have: unusual bruising or bleeding, fever, confusion, tiredness or irritability, stomach pain, vomiting, dark urine, fast heartbeats, and little or no urination.

Call your doctor at once if you have:

low red blood cells (anemia) - pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet;

signs of an electrolyte imbalance - muscle spasms or contractions, numbness or tingly feeling, nausea, fast or irregular heartbeats, seizure; or

capillary leak syndrome - dizziness, weakness, cough, trouble breathing, and sudden swelling or weight gain.

Serious side effects may be more likely in older adults.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common Lumoxiti side effects may include:

swelling in your arms, legs, or face;

nausea, diarrhea, constipation;

headache, tiredness;

fever; or

anemia.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Lumoxiti

To make sure Lumoxiti is safe for you, tell your doctor if you have ever had:

kidney disease; or

a condition that affects your blood and blood vessels (such as hemolytic uremic syndrome or severe thrombotic microangiopathy).

You may need to have a negative pregnancy test before starting this treatment.

Do not use Lumoxiti if you are pregnant. It could harm the unborn baby. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 30 days after your last dose. Tell your doctor right away if you become pregnant.

You should not breastfeed while using Lumoxiti.

Relate drugs

How to use Lumoxiti

Usual Adult Dose for Hairy Cell Leukemia:

0.04 mg/kg IV over 30 minutes on Days 1, 3, and 5 of each 28-day cycle for a maximum of 6 cycles, disease progression, or unacceptable toxicity Recommended Concomitant Treatment: -Hydrate with 1 L of isotonic solution (e.g., 5% dextrose injection, and 0.45% or 0.9% sodium chloride injection) over 2 to 4 hours before and after each infusion. -Administer 0.5 L to patients under 50 kg. -Advise patients to hydrate with up to 3 L of oral fluids (e.g., water, milk, or juice) per 24 hours on Days 1 through 8 of each 28-day cycle. In patients under 50 kg, up to 2 L per 24 hours is recommended. Comments: -Premedicate 30 to 90 minutes prior to each infusion with and antihistamine (e.g., hydroxyzine or diphenhydramine), acetaminophen, and a histamine-2 receptor antagonist (e.g., ranitidine, famotidine, or cimetidine). -Consider oral antihistamines and antipyretics for up to 24 hours following the infusion and an oral corticosteroid (e.g., 4 mg dexamethasone) to decrease nausea and vomiting. Maintain adequate oral fluid intake. -Monitor fluid balance and serum electrolytes. -Consider low-dose aspirin on Days 1 through 8 of each 28-day cycle. -Monitor for thrombosis. Use: For the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog (PNA)

Warnings

Call your doctor right away if you have signs of a rare but serious condition called capillary leak syndrome: dizziness, weakness, cough, trouble breathing, and sudden swelling or weight gain.

Lumoxiti can make you more likely to get infections or may worsen any current infections. Avoid contact with people who have infections that may spread to others (such as chickenpox, measles, flu). Consult your doctor if you have been exposed to an infection or for more details.

Moxetumomab pasudotox can damage your kidneys, especially if you already have kidney disease or if you are 65 years of age or older. Get emergency medical help if you have: unusual bruising or bleeding, fever, confusion, tiredness or irritability, stomach pain, vomiting, dark urine, fast heartbeats, and little or no urination.

What other drugs will affect Lumoxiti

Other drugs may interact with moxetumomab pasudotox, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.